The Priority Review: data and method Reasons clinical trials stopped early, completion dates 2016 to 2026 Prepared November 14, 2026. Editor: Nick Bostic. Questions and corrections: news@thepriorityreview.com SUMMARY Industry sponsors now cite a sponsor or business decision for about 6 in 10 trials they stop early, up from about 3 in 10 in 2016. At other sponsors, enrollment is still the reason given most often, and funding is the reason that grew. SOURCE ClinicalTrials.gov API version 2, pulled November 14, 2026. Query: interventional studies with overall status Terminated and a completion date from January 1, 2016 through October 31, 2026. The query returned 18,422 studies. Of these, 17,652 have completion dates from 2016 through 2025 and 770 have completion dates from January through October 2026. Query URL: https://clinicaltrials.gov/api/v2/studies?filter.overallStatus=TERMINATED&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BCompletionDate%5DRANGE%5B2016-01-01%2C2026-10-31%5D&countTotal=true&pageSize=20&fields=NCTId%2CBriefTitle METHOD Each study's Why Study Stopped text was sorted by the keyword rules printed at the end of this file. A reason can match more than one group, so the shares add to more than 100 percent. Shares are of trials that gave a reason. Industry means the lead sponsor class is INDUSTRY in the registry; other sponsors means every other lead sponsor class (universities, hospitals, government bodies, networks, individuals). Year means the year of the completion date. Completed-trial counts for the terminated share come from the same API with overall status Completed. ALL SPONSORS, 2016 THROUGH 2025 Trials: 17,652. Gave a reason: 16,906. - enrollment, accrual or recruitment: 6,828 trials, 40.4% - a sponsor or business decision: 3,090 trials, 18.3% - funding: 1,687 trials, 10.0% - efficacy or futility: 1,589 trials, 9.4% - COVID-19: 1,499 trials, 8.9% - safety: 623 trials, 3.7% - product supply: 547 trials, 3.2% - investigator or site staffing: 1,057 trials, 6.3% - no group matched: 2,854 trials, 16.9% INDUSTRY-SPONSORED TRIALS BY COMPLETION YEAR year | terminated | gave a reason | sponsor or business decision | enrollment | funding | efficacy or futility | safety | COVID-19 | completed | terminated share of terminated plus completed 2016 | 467 | 340 | 107 (31.5%) | 108 (31.8%) | 8 (2.4%) | 51 (15.0%) | 17 (5.0%) | 0 (0.0%) | 3,480 | 467 of 3,947 (11.8%) 2017 | 471 | 396 | 112 (28.3%) | 109 (27.5%) | 7 (1.8%) | 53 (13.4%) | 25 (6.3%) | 0 (0.0%) | 3,599 | 471 of 4,070 (11.6%) 2018 | 505 | 440 | 136 (30.9%) | 121 (27.5%) | 9 (2.0%) | 75 (17.0%) | 25 (5.7%) | 0 (0.0%) | 3,427 | 505 of 3,932 (12.8%) 2019 | 472 | 447 | 142 (31.8%) | 116 (26.0%) | 13 (2.9%) | 70 (15.7%) | 32 (7.2%) | 5 (1.1%) | 3,588 | 472 of 4,060 (11.6%) 2020 | 564 | 547 | 201 (36.7%) | 117 (21.4%) | 15 (2.7%) | 92 (16.8%) | 27 (4.9%) | 96 (17.6%) | 3,089 | 564 of 3,653 (15.4%) 2021 | 583 | 576 | 228 (39.6%) | 128 (22.2%) | 15 (2.6%) | 95 (16.5%) | 30 (5.2%) | 69 (12.0%) | 3,519 | 583 of 4,102 (14.2%) 2022 | 760 | 756 | 361 (47.8%) | 185 (24.5%) | 20 (2.6%) | 82 (10.8%) | 40 (5.3%) | 52 (6.9%) | 3,928 | 760 of 4,688 (16.2%) 2023 | 846 | 842 | 436 (51.8%) | 163 (19.4%) | 27 (3.2%) | 112 (13.3%) | 54 (6.4%) | 24 (2.9%) | 4,024 | 846 of 4,870 (17.4%) 2024 | 752 | 749 | 438 (58.5%) | 128 (17.1%) | 25 (3.3%) | 106 (14.2%) | 33 (4.4%) | 5 (0.7%) | 3,845 | 752 of 4,597 (16.4%) 2025 | 652 | 641 | 407 (63.5%) | 79 (12.3%) | 16 (2.5%) | 87 (13.6%) | 36 (5.6%) | 1 (0.2%) | 3,445 | 652 of 4,097 (15.9%) 2026 (January through October) | 329 | 329 | 203 (61.7%) | 37 (11.2%) | 11 (3.3%) | 53 (16.1%) | 27 (8.2%) | 1 (0.3%) | 2,116 | 329 of 2,445 (13.5%) OTHER SPONSORS BY COMPLETION YEAR year | terminated | gave a reason | sponsor or business decision | enrollment | funding | efficacy or futility | safety | COVID-19 | completed | terminated share of terminated plus completed 2016 | 1,054 | 960 | 25 (2.6%) | 504 (52.5%) | 105 (10.9%) | 76 (7.9%) | 30 (3.1%) | 1 (0.1%) | 9,329 | 1,054 of 10,383 (10.2%) 2017 | 1,138 | 1,030 | 45 (4.4%) | 568 (55.1%) | 119 (11.6%) | 65 (6.3%) | 39 (3.8%) | 3 (0.3%) | 9,835 | 1,138 of 10,973 (10.4%) 2018 | 1,142 | 1,060 | 37 (3.5%) | 550 (51.9%) | 134 (12.6%) | 69 (6.5%) | 21 (2.0%) | 9 (0.8%) | 10,686 | 1,142 of 11,828 (9.7%) 2019 | 1,162 | 1,103 | 53 (4.8%) | 557 (50.5%) | 153 (13.9%) | 75 (6.8%) | 31 (2.8%) | 55 (5.0%) | 11,543 | 1,162 of 12,705 (9.1%) 2020 | 1,432 | 1,402 | 48 (3.4%) | 558 (39.8%) | 159 (11.3%) | 76 (5.4%) | 35 (2.5%) | 501 (35.7%) | 10,859 | 1,432 of 12,291 (11.7%) 2021 | 1,284 | 1,275 | 52 (4.1%) | 624 (48.9%) | 171 (13.4%) | 79 (6.2%) | 35 (2.7%) | 307 (24.1%) | 11,069 | 1,284 of 12,353 (10.4%) 2022 | 1,266 | 1,250 | 70 (5.6%) | 632 (50.6%) | 176 (14.1%) | 96 (7.7%) | 34 (2.7%) | 214 (17.1%) | 12,706 | 1,266 of 13,972 (9.1%) 2023 | 1,145 | 1,141 | 64 (5.6%) | 580 (50.8%) | 177 (15.5%) | 70 (6.1%) | 28 (2.5%) | 101 (8.9%) | 13,675 | 1,145 of 14,820 (7.7%) 2024 | 1,077 | 1,076 | 58 (5.4%) | 564 (52.4%) | 169 (15.7%) | 84 (7.8%) | 29 (2.7%) | 40 (3.7%) | 14,192 | 1,077 of 15,269 (7.1%) 2025 | 880 | 875 | 70 (8.0%) | 437 (49.9%) | 169 (19.3%) | 76 (8.7%) | 22 (2.5%) | 16 (1.8%) | 13,345 | 880 of 14,225 (6.2%) 2026 (January through October) | 441 | 416 | 35 (8.4%) | 204 (49.0%) | 87 (20.9%) | 37 (8.9%) | 9 (2.2%) | 1 (0.2%) | 8,011 | 441 of 8,452 (5.2%) ALL SPONSORS BY COMPLETION YEAR year | terminated | gave a reason | sponsor or business decision | enrollment | funding | efficacy or futility | safety | COVID-19 | completed | terminated share of terminated plus completed 2016 | 1,521 | 1,300 | 132 (10.2%) | 612 (47.1%) | 113 (8.7%) | 127 (9.8%) | 47 (3.6%) | 1 (0.1%) | 12,809 | 1,521 of 14,330 (10.6%) 2017 | 1,609 | 1,426 | 157 (11.0%) | 677 (47.5%) | 126 (8.8%) | 118 (8.3%) | 64 (4.5%) | 3 (0.2%) | 13,434 | 1,609 of 15,043 (10.7%) 2018 | 1,647 | 1,500 | 173 (11.5%) | 671 (44.7%) | 143 (9.5%) | 144 (9.6%) | 46 (3.1%) | 9 (0.6%) | 14,113 | 1,647 of 15,760 (10.5%) 2019 | 1,634 | 1,550 | 195 (12.6%) | 673 (43.4%) | 166 (10.7%) | 145 (9.4%) | 63 (4.1%) | 60 (3.9%) | 15,131 | 1,634 of 16,765 (9.7%) 2020 | 1,996 | 1,949 | 249 (12.8%) | 675 (34.6%) | 174 (8.9%) | 168 (8.6%) | 62 (3.2%) | 597 (30.6%) | 13,948 | 1,996 of 15,944 (12.5%) 2021 | 1,867 | 1,851 | 280 (15.1%) | 752 (40.6%) | 186 (10.0%) | 174 (9.4%) | 65 (3.5%) | 376 (20.3%) | 14,588 | 1,867 of 16,455 (11.3%) 2022 | 2,026 | 2,006 | 431 (21.5%) | 817 (40.7%) | 196 (9.8%) | 178 (8.9%) | 74 (3.7%) | 266 (13.3%) | 16,634 | 2,026 of 18,660 (10.9%) 2023 | 1,991 | 1,983 | 500 (25.2%) | 743 (37.5%) | 204 (10.3%) | 182 (9.2%) | 82 (4.1%) | 125 (6.3%) | 17,699 | 1,991 of 19,690 (10.1%) 2024 | 1,829 | 1,825 | 496 (27.2%) | 692 (37.9%) | 194 (10.6%) | 190 (10.4%) | 62 (3.4%) | 45 (2.5%) | 18,037 | 1,829 of 19,866 (9.2%) 2025 | 1,532 | 1,516 | 477 (31.5%) | 516 (34.0%) | 185 (12.2%) | 163 (10.8%) | 58 (3.8%) | 17 (1.1%) | 16,790 | 1,532 of 18,322 (8.4%) 2026 (January through October) | 770 | 745 | 238 (31.9%) | 241 (32.3%) | 98 (13.2%) | 90 (12.1%) | 36 (4.8%) | 2 (0.3%) | 10,127 | 770 of 10,897 (7.1%) SHORT BUSINESS REASONS, INDUSTRY A business reason of four words or fewer (for example "Sponsor decision", "Business decision", "Company decision"). - 2016: 34 of 340 industry reasons; 18 read "Sponsor decision" and nothing more - 2025: 151 of 641 industry reasons; 61 read "Sponsor decision" and nothing more INDUSTRY TRIALS BY PHASE (a trial listed under two phases counts in both) - phase 1, 2016 through 2019: 477 reasons; sponsor or business decision 40.0%, enrollment 17.8%, efficacy or futility 10.7% - phase 1, 2022 through 2025: 1,220 reasons; sponsor or business decision 68.0%, enrollment 11.2%, efficacy or futility 7.5% - phase 2, 2016 through 2019: 601 reasons; sponsor or business decision 31.9%, enrollment 24.0%, efficacy or futility 20.8% - phase 2, 2022 through 2025: 1,273 reasons; sponsor or business decision 57.7%, enrollment 16.7%, efficacy or futility 14.5% - phase 3, 2016 through 2019: 299 reasons; sponsor or business decision 25.8%, enrollment 22.7%, efficacy or futility 27.4% - phase 3, 2022 through 2025: 511 reasons; sponsor or business decision 51.1%, enrollment 15.1%, efficacy or futility 26.2% REASONS THAT NAME A FEDERAL FUNDER, COMPLETION YEAR 2025 (all sponsors, any label) 18 reasons contain NIH, National Institutes of Health, NCI, National Cancer Institute, USAID or federal. Read one by one, at least 16 say the NIH, the National Cancer Institute, USAID or a federal funder ended a grant or the study: NCT06274359, NCT06785103, NCT05446064, NCT06367699, NCT07017595, NCT05390541, NCT07146139, NCT06215664, NCT05778578, NCT03904862, NCT05998616, NCT05826561, NCT06595745, NCT06065631, NCT06445751, NCT04587869. Two mention the words for a different reason: NCT05968638, NCT06939946. A keyword search can miss reasons that name no agency. PHASE MIX, INDUSTRY Phase 1 trials were 87 of the 340 industry reasons in 2016 and 296 of the 641 in 2025. PARTICIPANTS IN TRIALS THAT CITE ENROLLMENT, 2016 THROUGH 2025 Trials that cite enrollment and report an actual enrollment count: 6,767. Participants enrolled: 363,015. Median per trial: 13. Trials with 10 or fewer participants: 3,022. The total includes a few very large trials; the largest enrolled 23,578. CHECK SAMPLE 150 reasons were drawn at random (seed 577) after the enrollment, business and funding rules were final, and read against their labels in two separate passes: once by the software that drafted the analysis and once by a separate software review. Where the passes differed the less favorable count is given. The editor reads the piece before publication. Enrollment label: marked 59 reasons, right for 55, wrong for 4, and missed 5 others. Sponsor or business decision label: marked 26, right for 20 with every arguable case counted as wrong, and missed 2. Funding label: marked 12, right for 12. LIMITS The field holds the sponsor's own account. The registry does not record whether slow enrollment, weak data or cost sits behind a reason such as "sponsor decision". Keyword rules mislabel some reasons, as the check sample shows. Records for 2025 and 2026 are still being updated by sponsors, so those two years are incomplete, and this file does not measure whether some kinds of reason are updated sooner than others; the same lag affects the completed counts. Each trial counts once, whatever its size. The 2016 through 2025 set includes trials with no United States site: 10,642 of the 17,652 have one. The mix of phases changed over the period (see PHASE MIX). The 2015 study below read each reason by hand, gave each trial one reason and used all 905 trials as its base; this file uses keyword rules, several labels per reason and trials that gave a reason as its base. A trial counts once per year of completion date; the completion date of a terminated trial is the date of the last participant's last visit as the sponsor reports it. PRIOR WORK Williams RJ, Tse T, DiPiazza K, Zarin DA. Terminated Trials in the ClinicalTrials.gov Results Database. PLoS One 2015. Of 905 terminated trials with posted results, 350 (39%) cited an insufficient rate of accrual and 77 an unspecified business decision or strategic reason. KEYWORD RULES (regular expressions, not case sensitive) enrollment: accru|recruit|enrol|inclusion|participation|unavailability of (the )?(subject|patient|participant)|low (number|participation|patient|subject|census|volume)|lack of (patient|participant|subject|eligible|interest|referr)|insufficient (number|patient|participant|subject|sample)|(not enough|too few|few|no|unable to (find|identify)|difficult\w* (in )?(finding|identifying)) (eligible |suitable |qualifying )?(patient|participant|subject|candidate|volunteer)|sample size (was )?not|screen fail|eligible (patient|participant|subject)s? (were|was)? ?(not|rare|scarce)|feasib funding: \bfund|financ|budget|\bgrant|resource|money|sponsorship|lack of support|bankrupt|insolven|liquidat|ceased operations|out of business business: business|strateg|portfolio|commercial|priorit|company decision|corporate|sponsor'?s? decision|sponsor decision|decision (by|of|from) (the )?sponsor|sponsor (decided|elected|chose|terminated|request|discontinu|withdr|stopped|closed|cancel)|terminated by (the )?sponsor|administrative|acqui|merger|marketing|market (reason|condition|consideration|potential|landscape|dynamic|change)|develop\w*.{0,60}(terminat|discontinu|stop|halt|ceas)|(terminat|discontinu|stop|halt|ceas)\w*.{0,60}(development|program)|decided (to )?(not|terminate|discontinue|stop|close|end) efficacy_futility: futil|efficacy|ineffect|lack of (effect|benefit|response|activity)|no (significant |clinical |meaningful )?(effect|benefit|difference|improvement|response)|interim analys|did not (meet|show|demonstrate|reach)|not (meet|met|show|demonstrat)|negative result|primary endpoint|failed to (meet|show|demonstrate|achieve)|did not achieve|insufficient (activity|response|effect|benefit)|low response|unlikely to|statistical safety: safety|toxic|adverse|side effect|risk[- ]benefit|benefit[- ]risk|benefit/risk|risk/benefit|death|mortality|\bharm|tolerab|\bsae|risk profile|risks? (exceed|outweigh) covid: covid|corona|sars[- ]?cov|pandemic supply: no more .{0,30}available|not available|(removed|withdrawn) from (the )?(u\.?s\.? )?market|suppl(y|ier)|drug (availability|shortage|unavailab|expir)|unavailab|no longer (available|produc|manufactur|market)|manufactur|shortage|expir|recall|device (was |is )?(no longer|not available|unavailable|discontinued)|withdrawn from (the )?market|product (was )?discontinued investigator_site: \bpi\b|principal investigator|investigator (left|leav|depart|moved|relocat|retire|decision|decided|no longer|chang)|left (the )?(institution|university|hospital|center)|relocat|retire|staff|personnel|coordinator|passed away|site clos|departure A safety, efficacy, enrollment or business match is dropped when the words appear only in a phrase that rules the reason out (for example "not related to safety", "enrollment was completed", "agency priorities"). The full script is available on request.